The Pediatric Cancer Program performs basic, translational, and clinical research with the goal of improving diagnostic, prognostic, and therapeutic approaches for childhood cancer. The Pediatric Program is a component of Texas Children?s Cancer Center (TCCC), a joint center of BCM and Texas Children?s Hospital (TCH) and is one of the country?s largest pediatric cancer programs. The Center sees approximately 600 new pediatric cancer patients each year. Its main laboratory research facilities are located at TCH. The Pediatric Program includes 28 Research and 17 Clinical Members from a number of Departments including Pediatrics, Surgery, Neurosurgery, Pathology, Medicine and Psychology. The Program?s scientific aims include, 1) to increase our biological understanding of pediatric malignancies through comprehensive molecular, genomic and proteomic analysis of these diseases, 2) to use the information from these studies to improve diagnostic, prognostic, and therapeutic approaches for pediatric cancers, 3) to identify novel molecular targets that may be exploited therapeutically, 4) to study the genetic pre-disposition for selected pediatric cancers and determine the appropriate surveillance regimens for these at-risk children, 5) to identify effective new therapies for childhood malignancies and develop and conduct innovative Phase I and Phase II trials, 6) to study the late effects of childhood cancer therapy and improve the outcomes of survivors, 7) to mentor and train pediatric oncology fellows and post-fellowship research trainees to develop the next generation of leaders and 8) to impact pediatric cancer in our catchment area, nationally and internationally. As of September 1, 2014, the Pediatric Program had $5,764,212 in active NCI grants, $4,939,272 in Total Other NIH funding, $5,261,666 in other Peer Reviewed Funding, $3,344,907 in Non-Peer Reviewed Funding, for Total Funding of $19,310,057. In the last 5 years members of the Program published 404 cancer related manuscripts in peer-reviewed journals of which 33% represented intra-programmatic collaborations, 25% inter-programmatic and 58% inter- institutional. The Program?s research accomplishments have occurred in six thematic areas organized into formal research programs including: Biologic and Therapeutic Studies of Pediatric Solid Tumors, Pediatric Neuro-oncology Research, Pediatric Cancer Genetics and Genomics, Pediatric Cancer Developmental Therapeutics, Leukemia and Lymphoma, and Cancer Survivorship. These programs facilitate and organize thematic research activities, are trans-disciplinary and involve both laboratory and clinical researchers. Programs meet regularly to discuss research collaborations and research strategy including moving projects along the translational continuum from basic research to clinical studies. The Program has 116 cancer related protocols; 64 are clinical trials, 8 developed by Program investigators. The Program has robust educational and training components including the largest accredited pediatric hematology-oncology fellowship program and three NIH training grants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA125123-12S2
Application #
9759885
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lin, Alison J
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
12
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Disney-Hogg, Linden; Sud, Amit; Law, Philip J et al. (2018) Influence of obesity-related risk factors in the aetiology of glioma. Br J Cancer 118:1020-1027
Szwarc, Maria M; Kommagani, Ramakrishna; Putluri, Vasanta et al. (2018) Steroid Receptor Coactivator-2 Controls the Pentose Phosphate Pathway through RPIA in Human Endometrial Cancer Cells. Sci Rep 8:13134
Kruse, Robert L; Shum, Thomas; Tashiro, Haruko et al. (2018) HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy 20:697-705
Samaha, Heba; Pignata, Antonella; Fousek, Kristen et al. (2018) A homing system targets therapeutic T cells to brain cancer. Nature 561:331-337
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108
Lu, Lianghao; Wen, Yefei; Yao, Yuan et al. (2018) Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics 8:2189-2201
Martini-Stoica, Heidi; Cole, Allysa L; Swartzlander, Daniel B et al. (2018) TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med 215:2355-2377
Wang, Changjun; Zaheer, Mahira; Bian, Fang et al. (2018) Sjögren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice. Int J Mol Sci 19:
Singh, Ramesh; Karri, Dileep; Shen, Hong et al. (2018) TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest 128:3129-3143
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746

Showing the most recent 10 out of 991 publications